Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at ...

H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...

Let's machine some parts and assemble! Not as simple as v-wheels and extrusions, but a lot more fun :) We do some milling, ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating yesterday.Invest with Confidence: ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

FREDERICK, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...

(RTTNews) - Cartesian Therapeutics, Inc. (RNAC), a clinical-stage biotechnology company, on Monday announced that it has received written agreement from the U.S. Food and Drug Administration or ...

Cartesian Therapeutics develops mRNA cell therapies for autoimmune diseases, leveraging three modalities: mRNA CAR-T, mRNA MSC, and mRNA in situ. Lead asset Descartes-08 targets myasthenia gravis ...

周二，H.C. Wainwright重申对Cartesian Therapeutics股票的买入评级，维持45.00美元的目标价，较当前19.42美元的交易价格有显著上涨空间。该公司分析师Mitchell S. Kapoor在Cartesian Therapeutics最近的监管更新后提供了见解。根据 InvestingPro ...

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering ...